My Toolbox    |   Contact Us   |   Help    |   Sign In       

Home   |   Programs & Loans   |   Resources   |   Glossary   |   FAQs

  

Don't have an Account? Sign Up . It's Free

 Sign In to Your Account

E-mail Address* Password*
Forgot your Password?           * Required fields
    

 Why Sign Up for an Account?

Our tools will help you create a personalized business plan and financial statements. And all of it is free for everyone!

Business Plan

Use our easy, step-by-step form to generate your business plan. You can even use our sample business plan as a helpful guide.

Financial Reports

Answer the questions in our three step interview process and you will immediately be presented a Profit & Loss statement, and Cash Flow statement, and a Balance Sheet - all customized to your business.                               

Home

Sample Business Plan & Financial Reports

Your business plan is the road map for your business. It clearly defines your business, identifies your goals, and describes in detail where you are today, where you plan to be in the future, and how you are going to get there. Your business plan, like your business, is a living thing. No business remains static, the plan will need to be revisited periodically and updated to reflect changes in your business. Our website will save your plan for five years from the last time you visited it, unless you personally delete it. You can come back and edit it as often as you need.

View Sample


Industry News


FDA approves new treatment for diabetic retinopathy in patients with diabetic macular edema 3/25/2015
The U.S. Food and Drug Administration today expanded the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema.
FDA approves treatment for inhalation anthrax 3/25/2015
The U.S. Food and Drug Administration today approved Anthrasil, Anthrax Immune Globulin Intravenous (Human), to treat patients with inhalational anthrax in combination with appropriate antibacterial drugs.
FDA approves blood pump system to help patients maintain stable heart function during certain high-risk cardiac procedures 3/23/2015
The U.S. Food and Drug Administration today approved the Impella 2.5 System, a miniature blood pump system intended to help certain patients maintain stable heart function and circulation during certain high-risk percutaneous coronary intervention (HRPCI) procedures, such as balloon angioplasty and stenting, which re-open coronary arteries that are narrowed or blocked due to severe coronary artery disease (CAD).
FDA concludes Arctic Apples and Innate Potatoes are safe for consumption 3/20/2015
Today, the U.S. Food and Drug Administration completed its evaluation for two varieties of apples genetically engineered by Okanagan Specialty Fruits, Inc., and for six varieties of potatoes genetically engineered by J. R. Simplot Company and concluded that these foods are as safe and nutritious as their conventional counterparts.
FDA approves Cholbam to treat rare bile acid synthesis disorders 3/17/2015
Today the U.S. Food and Drug Administration approved Cholbam (cholic acid) capsules, the first FDA approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders (including Zellweger spectrum disorders). Patients with these rare, genetic, metabolic conditions exhibit manifestations of liver disease, steatorrhea (presence of fat in the stool) and complications from decreased fat-soluble vitamin absorption.
FDA releases final guidance on reprocessing of reusable medical devices 3/12/2015
The U.S. Food and Drug Administration today announced new actions to enhance the safety of reusable medical devices and address the possible spread of infectious agents between uses.
Federal judge enters consent decree against Specialty Compounding LLC 3/11/2015
U.S. District Judge Lee Yeakel entered a consent decree of permanent injunction on March 10, 2015 between the United States and Specialty Compounding LLC, of Cedar Park, Texas, and the company’s co-owners, Raymond L. Solano, III and William L. Swail. According to the complaint filed with the consent decree, Specialty Compounding manufactured purportedly sterile injectable drug products that tested positive for bacterial contamination. The U.S. Department of Justice brought the action on behalf of the U.S. Food and Drug Administration.
FDA approves first therapy for high-risk neuroblastoma 3/10/2015
The U.S. Food and Drug Administration today approved Unituxin (dinutuximab) as part of first-line therapy for pediatric patients with high-risk neuroblastoma, a type of cancer that most often occurs in young children.
FDA approves CPR devices that may increase chance of surviving cardiac arrest 3/9/2015
The U.S. Food and Drug Administration today approved the ResQCPR System, a system of two devices for first responders to use while performing cardiopulmonary resuscitation (CPR) on people whose hearts stop beating (cardiac arrest). The devices may improve the patient’s chances of surviving cardiac arrest.
FDA approves new antifungal drug Cresemba 3/6/2015
The U.S. Food and Drug Administration today approved Cresemba (isavuconazonium sulfate), a new antifungal drug product used to treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections.
FDA authorizes use of first device to treat patients with dialysis-related amyloidosis 3/6/2015
The U.S. Food and Drug Administration today authorized use of Lixelle Beta 2-microglobulin Apheresis Column, the first device to treat dialysis-related amyloidosis (DRA).
FDA approves first biosimilar product Zarxio 3/6/2015
The U.S. Food and Drug Administration today approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the U.S.
FDA expands approved use of Opdivo to treat lung cancer 3/4/2015
The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
FDA launches drug shortages mobile app 3/4/2015
Today, the U.S. Food and Drug Administration launched the agency’s first mobile application (app) specifically designed to speed public access to valuable information about drug shortages.
FDA approves new antibacterial drug Avycaz 2/25/2015
The U.S. Food and Drug Administration today approved Avycaz (ceftazidime-avibactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options.
FDA approves Farydak for treatment of multiple myeloma 2/23/2015
The U.S. Food and Drug Administration today approved Farydak (panobinostat) for the treatment of patients with multiple myeloma.
FDA approves closure system to permanently treat varicose veins 2/20/2015
The U.S. Food and Drug Administration today approved the VenaSeal closure system (VenaSeal system) to permanently treat varicose veins of the legs by sealing the affected superficial veins using an adhesive agent.
FDA permits marketing of first direct-to-consumer genetic carrier test for Bloom syndrome 2/19/2015
The U.S. Food and Drug Administration today authorized for marketing 23andMe’s Bloom Syndrome carrier test, a direct-to-consumer (DTC) genetic test to determine whether a healthy person has a variant in a gene that could lead to their offspring inheriting the serious disorder.
FDA issues new draft documents related to compounding of human drugs 2/13/2015
Today, the U.S. Food and Drug Administration issued five draft documents related to drug compounding and repackaging that will help entities comply with important public health provisions. The draft documents are applicable to pharmacies, federal facilities, outsourcing facilities and physicians.
FDA approves Lenvima for a type of thyroid cancer 2/13/2015
The U.S. Food and Drug Administration today granted approval to Lenvima (lenvatinib) to treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease).

Loan Calculator
This is a quick way for you to find out how much it might cost you to buy that new piece of equipment or even a house. Simply enter your desired loan amount, term/period of loan and your estimated percentage rate to calculate your likely monthly payment.

 Loan  Amount: $*  
 Terms in  Months: *  
 Interest  Rate:*  %
 

 

* Required fields


Programs and Loans [more]
Our Business Plans and Financial Reports are designed to be taken to any bank or lender and there are many programs available in the agricultural industry. Find a program or lender that is right for you today.

Resources [more]
We have provided links to useful resources. Please click on "more" to access them. You may also access these links after you have logged in by clicking on Resources located at the top of each page.

 

Privacy Statement   |   Contact Us